The human genome encodes 538 protein kinases that transfer a γ-phosphate group from
ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with …

MYC regulates a complex biological program by transcriptionally activating and repressing
its numerous target genes. As such, MYC is a master regulator of many processes, including …

Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

MicroRNAs (miRNAs) are a class of posttranscriptional regulators that have recently
introduced an additional level of intricacy to our understanding of gene regulation. There are …

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues is the second
volume of the 4th Edition of the WHO series on histological and genetic ty** of human …

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …

The bcr–abl oncogene, present in 95% of patients with chronic myelogenous leukemia
(CML), has been implicated as the cause of this disease. A compound, designed to inhibit …

Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with
myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors. An …

Exceptional advances in molecular biology and genetic research have expedited cancer
drug development tremendously. The declared paradigm is the development …

Chronic myeloid leukemia (CML) is probably the most extensively studied human
malignancy. The discovery of the Philadelphia (Ph) chromosome in 19601 as the first …